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Abstract
Background: Transforming growth factor-beta1 (TGF-b1) is a multipotential cytokine with angiogenic activity. There are
only limited data about its role in airway remodeling in COPD. We have previously shown that the reticular basement
membrane (Rbm) is hypervascular in the airways of current smokers either with or without chronic obstructive pulmonary
disease (COPD). This study evaluated TGF-b1 immunostaining in the Rbm and its relationship to vascularity in smokers with
or without COPD.
Methodology/Principal Findings: Bronchial biopsies from 15 smokers with normal lung function, 19 current and 14 ex-
smokers with COPD were immunostained for TGF-b1 antibody and compared to 17 healthy controls. The percentage area of
tissue and also number and area of vessels staining positively for TGF-b1 were measured and compared between groups.
Some bronchial biopsies from current smoking COPD subjects were also stained for phosphorylated (active) Smad2/3.
Epithelial TGF- b1 staining was not different between COPD current smokers and normal controls. TGF-b1 stained vessels in
the Rbm were increased in smokers with normal lung function, current smoking COPD and ex-smokers with COPD
compared to controls [median (range) for number of vessels/mm Rbm 2.5 (0.0–12.7), 3.4 (0.0–8.1) and 1.0 (0.0–6.3) vs. 0.0
(0.0–7.0), p,0.05]. Percentage of vessels stained was also increased in these clinical groups. Preliminary data suggest that in
current smoking COPD subjects endothelial cells and cells in the Rbm stain positively for phosphorylated Smad2/3
suggesting TGF-b1 is functionally active in this situation.
Conclusions/Significance: Vessel-associated TGF-b1 activity is increased in the bronchial Rbm in smokers and especially
those with COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a common
disease involving both lung parenchyma and airways [1,2,3].
Cigarette smoking is the most common cause of COPD [4].
Airway structural changes, termed as airway ‘‘remodeling’’, occur
during the course of the disease [5], but there are only a few
published papers on airway remodeling in COPD especially over
recent decades [6]. Angiogenesis (vascular development and new
vessel formation) is a component of remodeling in most chronic
inflammatory diseases including airway diseases such as asthma
[7–12].
Transforming growth factor-beta (TGF-b) is a multifunction
cytokine with angiogenic activity which is present in many tissues
and cells in the human body [12–18]. TGF-b1 is the most
abundant isoform [19], with both structural and inflammatory
cells being a source of TGF-b in the lungs [20,21]. A previous
study has shown a correlation between epithelial TGF-b and
vascular endothelial growth factor (VEGF), a well-known angio-
genic factor, in COPD bronchioles [22]. In addition, TGF- b
receptors are suggested to play an important role in the
pathogenesis of COPD through their regulation of Smad pathways
[23].
We have previously reported hypervascularity of the reticular
basement membrane (Rbm) of endo-bronchial biopsies (BB) from
smokers with or without COPD [24]. Increased vascularity in the
Rbm was associated with increased vessel-associated VEGF.
To further study angiogenic mediator expression in the BB and
examine its relationship with vascular changes in the mucosa, we
decided to stain our samples with anti-TGF-b1 monoclonal
antibody. We hypothesized that: 1. TGF-b1 is increased in the
Rbm in current smoking subjects, 2. TGF-b1 levels would
positively correlate with the changes in vascularity we have
previously described [24].
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Ethics Statement
The study was approved by Human Research Ethics Committee
(Tasmania) Network. All subjects provided written informed consent.
Study Design
This was a cross-sectional study.
Subjects
65 subjects were recruited through advertisement. BB from
15 smokers with normal lung function (S-N), 18 current smoking
COPD (S-COPD) and 13 ex-smokers with COPD (ES-COPD)
were compared with 17 healthy nonsmokers (H-N). COPD was
diagnosed according to the GOLD guidelines [4]. Subjects with
other respiratory diseases, a history of recent acute exacerbations
of COPD and those on systemic or inhaled corticosteroids over the
last 12 weeks were excluded from the study. COPD subjects were
on short-acting inhaled anticholinergics only.
Fiberoptic bronchoscopy. Was performed as previously
described [24]. There were no major complications from the
procedures.
Pulmonary function tests. Were performed and interpreted
according to ATS/ERS guidelines [25].
Tissue Processing
Biopsies were fixed in 10% neutral buffered formalin for two
hours, and then transferred to a 50% ethanol until being processed
using a Leica ASP 200 tissue processor, two 3-mm paraffin
embedded sections were cut for staining being separated by at least
50 microns and mounted on a slide.
After removal of paraffin, sections were stained with either
monoclonal antibody anti-TGF b1 (abcam ab 27969 clone TB1 at
1/16000 26.2561025 mg/ml- overnight at room temperature)
after blocking with Dako serum block (X0909) or phosphorylated
Smad2/3 (pSmad2/3) (Santa Cruz SC-11769R at 1/100 for
1hour at room temperature) following heat retrieval using a Dako
PT link with high pH solution K800421 at 95 degrees for
30 minutes. All slides were then treated to remove endogenous
peroxidase using 3% hydrogen peroxide. The primary antibody
was elaborated using either anti-mouse or anti-rabbit horseradish
peroxidase (HRP) conjugated DAKO Envision + reagent (K4001
or K4003) for secondary antibody binding and colour resolution
using Dako DAB+ (K3468). Nuclei were counterstained using
Mayers Haematoxylin and sections dehydrated through ascending
grades of ethanol, cleared in xylene and mounted in permount. An
equivalent isotype control using IgG1 (Dako X093101 or
X090310) was run with each section and a known lung tissue
positive tissue control was run with each staining.
Measurements Slides
Were coded and randomized to blind the person who did the
measurements. As many pictures as possible were taken from each
slide. Only areas with intact epithelium and LP and without any
holes or tissue damage were selected for photography. Overlap-
ping areas were avoided. Then, eight areas were randomly
selected for measurements. Measurements were performed using
computer-assisted image analysis (Image-Pro, version 5.1, Media
Cybernetics, USA) at x400 magnification.
The percent area of tissue stained for TGF-b1 in the epithelium
was measured using the automated software. The number and
cross-sectional area of vessels stained by TGF-b1 in the Rbm was
measured (Figure 1) and corrected for the length of the Rbm
before analyses. The percentage of total vessels in the Rbm
staining for TGF-b1 was calculated by dividing the number of
vessels stained for TGF-b1 by the total number of vessels stained
with anti-Collagen IV antibody. We used the vessel data collected
in our previous published study [24] which was done in sections
serially contiguous with those used currently. For TGF-b1 staining
the percentage of total vessels stained for TGF-b1 was sometimes
above 100% because of slight differences in the disposition of
countable vessels even in serial sections. We take such data to
mean in reality essentially 100% vessel staining, but the data has
not been normalized for this.
45 subjects had enough analyzable tissue for final analyses.
Statistical Analyses
Non-parametric ANOVA (Kruskal-Wallis) and post-hoc Mann-
Whitney U tests were used to test mean differences amongst all
study groups and between two groups respectively as the
distribution of variables were non-normal. Spearman’s rank
correlation coefficient was used to test for correlations between
outcomes. All analyses were performed using PASW statistics 18.
Two-tailed p values ,0.05 were considered as significant.
Results
Demographics of participants are summarized in Table 1. The
mean age of participants with COPD was greater than the
smokers with normal lung function or healthy non-smokers. The
total smoking history was greater and lung function measures were
lower in the COPD groups compared to smokers with normal lung
function or healthy non-smokers.
As we were mainly interested in the vessel changes in the Rbm
and since there was no significant difference in percent area of the
epithelium stained for TGF-b1 between the ‘‘extreme groups’’ S-
COPD and H-N groups [median (range) 6% (0–31) vs. 21% (0–
51) respectively, p=0.3] in the preliminary ‘‘scoping’’ study, no
further measurements were performed for the other two groups.
The number and area of vessels stained for TGF-b1 in the Rbm
were significantly different between groups (Kruskal-Wallis test,
p,0.01 for both comparisons), with S-N, S-COPD and ES-COPD
demonstrating a higher number of TGF-b1 stained vessels/mm
Rbm compared to the control group [median (range) for S-N 2.5
Figure 1. Vessels in the airway reticular basement membrane
(Rbm) stained for transforming growth factor-beta1 (TGF-b1).
The reticular basement membrane is indicated by a star beneath the
epithelium (EP). Vessels in the Rbm are indicated by arrows. Current
smoking COPD subject, X400, Scale =20 mm.
doi:10.1371/journal.pone.0039736.g001
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6.3) vs. H-N 0.0 (0.0–7.0)] (Figure 2). The area of vessels staining
for TGF-b1, expressed per mm
2/mm of Rbm, was also greater in
S-N, S-COPD and ES-COPD [median (range) 379 (0–2132), 324
(0–2882) and 155 (0–4029)] compared to the healthy control
group [median (range) 0 (0–545)], (p,0.01 for all comparisons).
Furthermore, the percentage of total vessels in the Rbm staining
for TGF-b1 was significantly different between groups (Kruskal-
Wallis test, p,0.05), with S-N, S-COPD and ES-COPD having a
higher percentage than the control group [median (range) for S-N
31% (0–121), for S-COPD 40% (0–123) and for ES-COPD 22%
(0–114) vs. H-N 0 (0–26)] (Figure 3).
Bronchial biopsy sections from S-COPD stained positively for
pSmad2/3 in the basal epithelium, cells in the Rbm, structural
cells in the lamina propria, and also in vessel endothelium.
Subjectively, this was strikingly more than in controls, but we do
not yet have sufficient data for a full analysis (Figure 4).
Correlations
The number of Rbm vessels stained for TGF-b1 correlated with
total vessel number stained with anti-Collagen IV antibody in the
ES-COPD and S-N groups, but not in the actively smoking
COPD group (S-COPD) (Table 2). The total vessels staining for
TGF-b1 in the Rbm correlated reasonably strongly with number
of vessels stained for vascular endothelial growth factor (VEGF,
measured in our previous study [24]) only in the S-COPD group,
but this did not reach statistical significance (r=0.6, p=0.1), but is
probably a type 2 error.
Discussion
This study found that in smokers with normal lung function and
in subjects with COPD, airway vessel staining for TGF-b1 was
increased in the Rbm. This finding could not be explained simply
by TGF-b1 vessel staining reflecting gross hypervascularity of the
Rbm, because the percentage of total vessels in the Rbm staining
for TGF-b1 which takes this into account was also increased. Total
number of vessels stained for TGF-b1 correlated with the total
Table 1. Demographics.
Groups* (numbers) H-N (n=17) S-N(n=15) S-COPD (n=19) ES-COPD (n=14) P value
Age
{ years 54(20–68) 46(30–65) 61(46–78) 61(53–69) ,0.01
Female/male 6/11 4/11 8/11 5/9 0.2 (NS)
1
Pack-years of smoking
{ 0 35(11–57) 45(18–82) 55(18–151) ,0.01
FEV1%
{{ 119(114–124) 100(78–125) 83(55–102) 83(55–105) ,0.01
FEV1/FVC%{{ 82(71–88) 78(70–96) 59(46–68) 57(38–68) ,0.01
DLCO% predicted
{ ml/min/mmHg – 77(58–105) 67(48–83) 64(45–74) ,0.01
*H-N: healthy and nonsmoker, S-N: smokers with normal lung function, S-COPD and ES-COPD: current smokers and ex-smokers with COPD.
{Median (range),
{ post-bronchodilator values,
1Chi-square test, NS = not significant.
doi:10.1371/journal.pone.0039736.t001
Figure 2. Number of vessels stained for transforming growth
factor-beta1 (TGF-b1) in the reticular basement membrane
(Rbm). Number of vessels are compared in healthy nonsmokers (H-N),
smokers with normal lung function (S-N), current smoking COPD (S-
COPD) and ex-smokers with COPD (ES-COPD).
doi:10.1371/journal.pone.0039736.g002
Figure 3. The percentage of vessels stained for transforming
growth factor-beta1 (TGF-b1). The percentage is compared in
healthy nonsmokers (H-N), smokers with normal lung function (S-N),
current smoking COPD (S-COPD) and ex-smokers with COPD (ES-COPD).
This ratio is calculated by division of the number of vessels stained for
TGF-b1 by the total number of vessels in the reticular basement
membrane (Rbm) marked with anti-Collagen IV antibody in serial
sections, which we assessed in our previous study (Soltani A. et al.,
Respiratory Research. 2010, 30;11:105). Variation in total number of
vessels between sections gives occasionally anomalous data-points
greater than 100%. The number of subjects in this plot is different from
Figure 3 because some individuals did not have enough tissue to
provide adequate consecutive sections for both types of immunostain-
ing.
doi:10.1371/journal.pone.0039736.g003
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groups and not in the group with more vessels, the S-COPD group
[24]. Thus, TGF-b1 would seem to have probably a role in vessel
remodeling in both smokers and in COPD but the extra effect in
S-COPD must be contributed by another factor.
There was a borderline positive correlation between total Rbm
vessels staining for TGF-b1 and vessel-associated VEGF in the
Rbm [24], but only in S-COPD. This might imply that in this
group VEGF is the additional factor that makes the Rbm so
relatively hypervascular. Thus, in smoking per se and in ES-
COPD, TGF-b1 is the angiogenic driver, but in S-COPD both
TGF-b1 and VEGF may be active. Epithelial TGF-b1 staining
was not different between COPD current smokers and normal
controls.
We observed positive staining for pSmad2/3 in the basal
epithelium, cells in the Rbm, structural cells in the lamina propria
and vessels in both the lamina propria and the Rbm in S-COPD.
Some staining was present in normal nonsmoking controls, but
subjectively was strikingly less. This suggests that TGF-b1 activity
may be increased in this compartment as well as merely
expression. Further work on this is ongoing.
The role of TGF-b1 in COPD pathogenesis is not clear. Some
studies have shown a relationship between TGF-b1 gene single
nucleotide polymorphisms and COPD development [26], but
published data on TGF-b1 protein expression in the airways or
lung parenchyma in COPD are both limited and contradictory.
Thus, there are three studies that have published data for TGF-b1
staining in the mucosa of large airways [27,28,29], but they
reported remarkably different results, which may reflect the
differences in their criteria for subject recruitment.
Zanini et al., using BB, found higher number of cells positive for
TGF-b1 in the LP in COPD subjects who were ex-smokers and
not on inhaled corticosteroids and there was a correlation between
cells positive for TGF-b1 and vascularity in the LP. Vessels related
to the Rbm and deeper lamina propria were not differentiated.
[27]. Kokturk et al. used BB to compare epithelial TGF-b1i n
COPD or asthma with controls [29] and did not find any
differences in epithelial and subepithelial TGF-b1 between COPD
and controls. Vignola et al. also used BB to compare TGF-b1i n
subjects with symptomatic chronic bronchitis (i.e. productive
cough) with or without COPD, asthma and controls and found
higher TGF-b1 levels in the epithelium and LP in chronic
bronchitis compared to the control group [28] with no apparent
relationship with COPD as such. Our data on TGF-b1 in the
epithelium is similar to that of Kokturk et al. [29] but contrasts to
that of Vignola et al. [28] However, Vignola et al. targeted
subjects with chronic bronchitis rather than COPD, and chronic
bronchitis was not one of our inclusion criteria and is not as
common in Australia as Europe. Not surprisingly, chronic
bronchitis was not a feature in our COPD subjects. We are the
first group which has studied TGF-b1 specifically in the bronchial
Rbm compartment of COPD subjects and S-N to examine its
relationship to hypervascularity of the Rbm. We believe that the
Rbm is a particularly pathogenic area in COPD [24,30], and may
have particular relevance to long-term outcomes such as cancer
development.
A few investigators have used resected lung tissue to study TGF-
b1 in the small airways and lung parenchyma in COPD [13,31].
Clearly these studies are not fully comparable to ours which has
used large airway endo-bronchial biopsies. One study found
higher airway and alveolar epithelial TGF-b1 in COPD subjects
without chronic bronchitis compared to controls [31], while
another compared current or ex-smokers with COPD to current
or ex-smokers without COPD and found higher TGF-b1i n
bronchiolar and alveolar epithelium in the COPD groups [13].
The drawback for these types of studies obviously is that they
cannot recruit truly healthy subjects and even their controls had
undergone thoracic surgery for a clinical indication, mostly
smoking-related lung cancer. Nevertheless, Takizawa et al. using
an ultra-thin bronchoscope for brushing of bronchiolar epithelial
cells [32] found higher epithelial TGF-b1 in smokers with normal
lung function as well as COPD subjects compared to normal
controls.
Figure 4. Phosphorylated (activated) Smad2/3 (pSmad2/3) staining of bronchial biopsies in normal nonsmoking controls (A) and
current smoking COPD subjects (B). Black arrows indicate vessels stained with pSmad2/3 in the bronchial Rbm in current smoking COPD. There
are very few vessels at all in the Rbm in normals and those that are there do not stain for pSmad2/3. X 400.
doi:10.1371/journal.pone.0039736.g004
Table 2. Correlation of total number of TGF-ß1 stained
vessels against total number of vessels.
Groups S-COPD ES-COPD S-N
Correlation coefficients r=0.1, p=0.7 r=0.6, P,0.05 r=0.6, P,0.05
All correlations are Spearman’s correlation coefficients.
Abbreviations: ES-COPD, ex-smokers with COPD; Rbm, reticular basement
membrane; S-COPD, Current smoking COPD; S-N, smokers with normal lung
function; TGF-b1, transforming growth factor-b1.
doi:10.1371/journal.pone.0039736.t002
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subjects in our other groups, but comprehensive regression
analyses did not show any relationship between age and our
positive findings, either for vessel numbers or angiogenic growth
factor staining.
In conclusion, vessel-associated TGF-b1 expression was in-
creased in both smokers and in COPD, but especially so in actively
smoking COPD. Regression analysis suggests that TGF-b1 may be
a driving factor for angiogenesis in these situations but that the
extra effect in S-COPD is likely to be due to something else,
probably VEGF. Preliminary data suggest that the TGF-b1i s
indeed functionally active through pSmad2/3 expression. The
Rbm may be of particularly pathological relevance in smokers and
COPD [24], with the Rbm demonstrating fragmentation, hyper-
vascularity and hyper-cellularity; the latter due to what we believe
are migrating and transitioning epithelial cells (epithelial mesen-
chymal transition, EMT) [24,30,33]. How these cells may
contribute to changes in ECM proteins, airway wall stiffness and
obstruction in COPD needs to be defined. Similarly, the role of
angiogenesis and EMT in smoking/COPD-related lung cancer
needs further definition. Longitudinal studies to evaluate the
effects of smoking cessation and also the effects of treatment,
particularly inhaled corticosteroids, on TGF-b1 level in BB are
also now indicated, as TGF-b1 may be a leading mediator for all
these other pathological features of COPD.
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